Published in Acta Trop on September 01, 2003
Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med (2005) 4.00
Buruli ulcer recurrence, Benin. Emerg Infect Dis (2005) 1.69
Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother (2013) 1.27
Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? Future Microbiol (2011) 1.20
Socio-cultural determinants of timely and delayed treatment of Buruli ulcer: Implications for disease control. Infect Dis Poverty (2012) 1.06
Buruli-ulcer induced disability in ghana: a study at apromase in the ashanti region. Plast Surg Int (2012) 0.96
Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection. PLoS One (2012) 0.92
What does detection of Mycobacterium ulcerans DNA in the margin of an excised Buruli ulcer lesion tell us? J Clin Microbiol (2006) 0.81
A Genomic Approach to Resolving Relapse versus Reinfection among Four Cases of Buruli Ulcer. PLoS Negl Trop Dis (2015) 0.76
Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet (2010) 5.02
Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med (2010) 3.04
Beliefs and attitudes toward Buruli ulcer in Ghana. Am J Trop Med Hyg (2002) 2.30
A new, simple and objective prognostic score for phase I cancer patients. Eur J Cancer (2011) 2.24
Risk factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study in Ghana. Clin Infect Dis (2005) 1.95
Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis (2003) 1.84
Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J (2013) 1.75
The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev (2004) 1.60
Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis (2011) 1.58
Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. Eur Respir J (2013) 1.58
Quality of interhospital transport of critically ill patients: a prospective audit. Crit Care (2005) 1.57
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet (2002) 1.57
Functional limitations after surgical or antibiotic treatment for Buruli ulcer in Benin. Am J Trop Med Hyg (2009) 1.49
Inhibition of p38 mitogen-activated protein kinase: dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans. Crit Care Med (2002) 1.49
Pandemic influenza and hospital resources. Emerg Infect Dis (2007) 1.44
Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease. Clin Infect Dis (2009) 1.43
Pandemic influenza and pediatric intensive care. Pediatr Crit Care Med (2010) 1.42
Analysis of an IS2404-based nested PCR for diagnosis of Buruli ulcer disease in regions of Ghana where the disease is endemic. J Clin Microbiol (2003) 1.33
Healthcare seeking behaviour for Buruli ulcer in Benin: a model to capture therapy choice of patients and healthy community members. Trans R Soc Trop Med Hyg (2008) 1.32
Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. Trop Med Int Health (2005) 1.29
Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects. Br J Nutr (2010) 1.27
Louse-borne relapsing fever (Borrelia recurrentis) in asylum seekers from Eritrea, the Netherlands, July 2015. Euro Surveill (2015) 1.19
Prone positioning of patients with acute respiratory failure. N Engl J Med (2002) 1.18
Impact of digestive and oropharyngeal decontamination on the intestinal microbiota in ICU patients. Intensive Care Med (2010) 1.18
Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev (2009) 1.14
The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer (2004) 1.14
Dry-reagent-based PCR as a novel tool for laboratory confirmation of clinically diagnosed Mycobacterium ulcerans-associated disease in areas in the tropics where M. ulcerans is endemic. J Clin Microbiol (2005) 1.12
Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana. Clin Diagn Lab Immunol (2005) 1.11
A stepwise approach to the laboratory diagnosis of Buruli ulcer disease. Trop Med Int Health (2007) 1.10
Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. Clin Ther (2010) 1.09
Susceptibility to Buruli ulcer is associated with the SLC11A1 (NRAMP1) D543N polymorphism. Genes Immun (2006) 1.09
Oral treatment for patients with Buruli ulcer co-infected with HIV: think twice. AIDS (2014) 1.07
Assessment of functional limitations caused by Mycobacterium ulcerans infection: towards a Buruli ulcer functional limitation score. Trop Med Int Health (2003) 1.07
Optimization of standard in-house 24-locus variable-number tandem-repeat typing for Mycobacterium tuberculosis and its direct application to clinical material. J Clin Microbiol (2014) 1.07
Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol (2009) 1.05
Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit (2010) 0.99
Ultrasound of the lung: just imagine. Intensive Care Med (2003) 0.99
Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis (2009) 0.99
Epidemiology of acute lung injury and acute respiratory distress syndrome in The Netherlands: a survey. Respir Med (2007) 0.98
Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet (2010) 0.98
Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998). Ann Oncol (2013) 0.98
A genotypic approach for detection, identification, and characterization of drug resistance in Mycobacterium ulcerans in clinical samples and isolates from Ghana. Am J Trop Med Hyg (2010) 0.97
Distribution of Buruli ulcer lesions over body surface area in a large case series in Ghana: uncovering clues for mode of transmission. Trans R Soc Trop Med Hyg (2005) 0.97
An 18-year-old man with rapidly progressive multiorgan failure after a positive mononucleosis spot test result. Chest (2006) 0.95
Family functioning and adolescents' emotional and behavioral problems: when a parent has cancer. Ann Oncol (2007) 0.95
Tailoring therapy in colorectal cancer by PET-CT. Q J Nucl Med Mol Imaging (2009) 0.93
Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. Eur Respir J (2012) 0.93
Clarithromycin significantly increases linezolid serum concentrations. Antimicrob Agents Chemother (2010) 0.92
Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. Cancer Imaging (2012) 0.92
Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol (2007) 0.92
Comparison of 14 molecular assays for detection of Mycobacterium tuberculosis complex in bronchoalveolar lavage fluid. J Clin Microbiol (2013) 0.92
Irradiation of rat brain reduces P-glycoprotein expression and function. Br J Cancer (2007) 0.91
Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. Eur J Surg Oncol (2012) 0.91
Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol (2012) 0.90
The quality of communication between parents and adolescent children in the case of parental cancer. Ann Oncol (2005) 0.89
Excision of pre-ulcerative forms of Buruli ulcer disease: a curative treatment? Infection (2008) 0.89
Management of BU-HIV co-infection. Trop Med Int Health (2014) 0.89
A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer. Br J Cancer (2010) 0.88
Perceptions on the effectiveness of treatment and the timeline of Buruli ulcer influence pre-hospital delay reported by healthy individuals. PLoS Negl Trop Dis (2013) 0.88
Low but sufficient anidulafungin exposure in critically ill patients. Antimicrob Agents Chemother (2013) 0.87
Cardiac troponin I release and cytokine response during experimental human endotoxaemia. Intensive Care Med (2003) 0.87
Strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response. Antimicrob Agents Chemother (2014) 0.87
Immunoglobulin M antibody responses to Mycobacterium ulcerans allow discrimination between cases of active Buruli ulcer disease and matched family controls in areas where the disease is endemic. Clin Diagn Lab Immunol (2004) 0.87
Modulation of death receptor pathways in oncology. Drugs Today (Barc) (2003) 0.86
Trimethoprim/sulfamethoxazole susceptibility of Mycobacterium tuberculosis. Int J Antimicrob Agents (2013) 0.86
Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy. Cancer Invest (2007) 0.86
[Distribution of Buruli ulcer in the Zè district of Benin]. Med Trop (Mars) (2010) 0.85
Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. Antimicrob Agents Chemother (2013) 0.85
Unusual cluster of HIV type 1 dual infections in Groningen, The Netherlands. AIDS Res Hum Retroviruses (2010) 0.85
Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann Oncol (2006) 0.85
Immunology in tuberculosis: challenges in monitoring of disease activity and identifying correlates of protection. Curr Pharm Des (2011) 0.85
Drug concentration in lung tissue in multidrug-resistant tuberculosis. Eur Respir J (2013) 0.84
Pandemic influenza and excess intensive-care workload. Emerg Infect Dis (2008) 0.84
Bronchoscopic diagnosis of pulmonary infiltrates in granulocytopenic patients with hematologic malignancies: BAL versus PSB and PBAL. Respir Med (2006) 0.84
Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer (2013) 0.84
Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients. Target Oncol (2013) 0.84
Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. Ann Oncol (2009) 0.84
Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells. Int J Oncol (2004) 0.84
Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies. Crit Rev Oncol Hematol (2002) 0.83
Measuring impairment caused by leprosy: inter-tester reliability of the WHO disability grading system. Lepr Rev (2004) 0.83
Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer. Breast (2013) 0.83
Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1-year analysis. Eur J Cancer (2004) 0.82
Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL. Br J Cancer (2008) 0.82
Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity. Br J Nutr (2010) 0.81
Towards rational use of antibiotics for suspected secondary infections in Buruli ulcer patients. PLoS Negl Trop Dis (2013) 0.81
Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. Ann Oncol (2002) 0.81
Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. Ther Drug Monit (2011) 0.80
Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease. Ther Drug Monit (2015) 0.80
Promises and challenges of positron emission tomography for assessment of sarcoma in daily clinical practice. Cancer Imaging (2008) 0.80
Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia. Emerg Infect Dis (2007) 0.80
Automated erythrocytapheresis in severe falciparum malaria: A critical appraisal. Acta Trop (2006) 0.80
Routine radiography does not have a role in the diagnostic evaluation of ambulatory adult febrile neutropenic cancer patients. Eur J Cancer (2003) 0.79
Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. Eur J Cancer (2003) 0.79
The role of oral mucositis on the systemic inflammation parameter IL-8 in febrile neutropenic cancer patients. Cancer Invest (2006) 0.77
Cancer in adolescents and young adults in north Netherlands (1989-2003): increased incidence, stable survival and high incidence of second primary tumours. Ann Oncol (2008) 0.77
Tumor-receptor imaging in breast cancer: a tool for patient selection and response monitoring. Curr Mol Med (2013) 0.77